



Review

Pharmaceutical spray freeze drying

Stefan Wanning^a, Richard Süverkrüp^a, Alf Lamprecht^{a,b,*}^a Laboratory of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, University of Bonn, Bonn, Germany^b Laboratory of Pharmaceutical Engineering (EA4267), University of Franche-Comté, Besançon, France

ARTICLE INFO

Article history:

Received 23 December 2014

Received in revised form 15 April 2015

Accepted 16 April 2015

Available online 18 April 2015

Keywords:

Spray freeze drying

Protein formulations

Lyophilisation

Porous particles

Pulmonary application

Vaccination

ABSTRACT

Pharmaceutical spray-freeze drying (SFD) includes a heterogeneous set of technologies with primary applications in apparent solubility enhancement, pulmonary drug delivery, intradermal ballistic administration and delivery of vaccines to the nasal mucosa. The methods comprise of three steps: droplet generation, freezing and sublimation drying, which can be matched to the requirements given by the dosage form and route of administration. The objectives, various methods and physicochemical and pharmacological outcomes have been reviewed with a scope including related fields of science and technology.

© 2015 Elsevier B.V. All rights reserved.

Contents

1.	Why to spray-freeze-dry medicinal products	137
2.	How to spray freeze dry medicinal products	137
2.1.	Generation of sprays and droplet streams	138
2.1.1.	Hydraulic nozzles	139
2.1.2.	Pneumatic atomisation	140
2.1.3.	Ultrasonic spray nozzles	140
2.1.4.	Piezoelectric droplet stream generation	140
2.1.5.	Thermal droplet stream generation	142
2.1.6.	Electrohydrodynamic droplet (EHD) generation	142
2.1.7.	Droplet stabilisation	142
2.2.	Droplet freezing	142
2.2.1.	Overview of spray freezing techniques	143
2.2.2.	Atmospheric freezing	143
2.2.3.	Spray-freezing with compressed carbon dioxide	144
2.2.4.	Freezing by spraying into vapor over a cryogenic liquid (SFV)	144
2.2.5.	Spray-freezing into liquid (SFL)	145
2.2.6.	Spray freezing onto solid surfaces (thin film freezing, TFF)	145
2.3.	Sublimation drying	145
2.3.1.	Atmospheric freeze drying	145
2.3.2.	Vacuum lyophilisation	146
2.4.	Solvents and excipients	146
2.4.1.	Solvents	146
2.4.2.	Excipients	147
3.	Findings	147

* Corresponding author at: Laboratory of Pharmaceutical Technology and Biopharmaceutics, Institute of Pharmacy, University of Bonn, Gerhard-Domagk-Str. 3, 53123 Bonn, Germany. Tel.: +49 228 735243; fax: +49 228 735268.

E-mail address: alf.lamprecht@uni-bonn.de (A. Lamprecht).

3.1.	Morphology of SFD powders	147
3.2.	Particle characteristics and size distribution	147
3.2.1.	Powders for pulmonary application	147
3.2.2.	Powders for nasal application	148
3.2.3.	Powders for needle-free ballistic intradermal application	148
3.3.	Solubility and dissolution rates of poorly soluble products	148
3.4.	Preprocessing for controlled release microspheres	149
3.5.	Stability of new biological entities (NBE) in SFD powders	149
3.6.	Therapeutic efficiency of SFD products	150
3.6.1.	Vaccines	150
3.6.2.	Insulin	150
3.6.3.	Recombinant human vascular-endothelial-growth-factor (rhVEGF)	150
3.6.4.	Dry plasmid DNA (pDNA)	150
3.6.5.	Doxorubicin	150
4.	General discussion	150
	Acknowledgements	151
	References	151

1. Why to spray-freeze-dry medicinal products

Since its introduction by Werly and Baumann, (1964), “spray-freeze drying” (SFD) has attracted much interest in various areas of research, though for the fulfillment of different objectives. The process has been widely used in pharmaceutical research, as well as food science and technology (Ishwarya et al., 2015).

In this review, we aim to provide an overview about the potentials of SFD for the development of pharmaceutical products. We will discuss the main steps involved within the production process (i.e., spraying, freezing and drying) and introduce, describe, and evaluate different available technical approaches related to each step. The findings of the reviewed papers are then discussed in terms of physical and therapeutic characteristics and are subsequently evaluated in regard with the intended pharmaceutical application.

Different approaches have been developed to enable the delivery of biologicals to the body. In addition to the well-known routes of administrations, less conventional pathways such as the pulmonary and nasal routes and delivery to the epidermis by needle-free injection have been investigated. The prime goal of exploring such administration pathways is to develop alternatives to parenteral injection (Schiffert et al., 2010; Klingler et al., 2009; Bi et al., 2008) and to enhance the drug targeting potential (Roa et al., 2011; Gao et al., 2011).

As an approach facilitating the development of dosage forms for alternative delivery pathways, SFD is preferred over classical spray-drying (SD) or freeze-drying (FD) for various reasons. First, using SFD methods can enhance the apparent solubility of poorly water-soluble drugs, which is a common problem with newly developed active pharmaceutical ingredients (API) (Vu et al., 2013). Additionally, due to an ultra-fast freezing process, the drug is embedded amorphously in the excipient thereby minimising the possibility of phase separation between drug and excipients and therefore leading to a molecular distribution of the drug in the excipient material.

Within the context of delivering biologicals as sustained release injectables, some research groups have used SFD for preprocessing the protein/peptide ingredient prior to encapsulation in poly (lactic-co-glycolic acid) (PLGA) microspheres. Others have used the process to enable the pulmonary, nasal, and needle-free epidermal drug delivery (e.g., non-invasive vaccination). Biologicals are usually freeze-dried in vials to enhance storage stability, but when aiming for the latter applications, a development of a flowable powder is mandatory. SFD offers the possibility to produce such powders with controlled particle-size distributions, and is hence more favorable than classic FD. On the other hand, SFD

is preferable over SD due to the possibility of processing thermo-sensitive ingredients (Cheow et al., 2011) and the improvement of the reconstitution characteristics of polymeric nanoparticles (Ali and Lamprecht, 2014). Furthermore, SFD is economically preferable over the conventional FD in vials. Lyophilisation of spray-frozen products is more favorable than that of parenteral formulations in vials both in terms of time and energy consumption (Bosshammer, 2014; Claussen et al., 2007). Moreover, SFD allows the production of a flowable bulk ware. This leads to an enormous increase in flexibility of a production site, as the dosage in vials can be adjusted very easily. Table 1 presents an overview of different applications of SFD techniques.

2. How to spray freeze dry medicinal products

The term “spray-freeze drying” (SFD) refers to processes with the following three steps in common:

- Dispersion of bulk liquid solutions into droplets,
- Droplet freezing, and
- Sublimation drying of the frozen material, which may comprise particles or a film that can be subsequently pulverised.

Obviously, some aspects of SFD are closely related to SD and lyophilisation operations, which are widely employed in both pharmaceutical and food industries, but the intricate interactions between rheological and surface phenomena with the transfer of matter and energy and fast transitions from the liquid to the solid and from the solid to the gaseous phase generate opportunities for new products with unique features but also new challenges, particularly with respect to current good manufacturing practices (GMP) and process analytical technologies. Similar combinations of spray-congealing and drying operations have been in use for some time in the production of uniform spherical particles for fertilizers, detergents and explosives, where the process is known as “prilling”.

In contrast to SD, where the size and shape of particles emerge upon drying, the size and essential features of the internal structure of lyophilised spherules originate from the freezing step, and with qualifications this holds also for the surface morphology. When droplets are frozen in flight, the particle size is nearly equal to that of the droplet. The surface of dried particles is spherical, usually covered with a smooth shell, which may be partially or completely missing, so that the irregular honeycomb of the internal structure becomes visible. Due to the high specific surface area, the maximal diffusion path length of solvent molecules is

Download English Version:

<https://daneshyari.com/en/article/2501347>

Download Persian Version:

<https://daneshyari.com/article/2501347>

[Daneshyari.com](https://daneshyari.com)